eFigure 1. Distribution of Participants by A) Number of Mild Attacks Treated and B) Number of Moderate or Severe Attacks Treated

A



B



eFigure 2. Pain Freedom at A) 24 Hours and B) 48 Hours Post Dose by Headache Severity Across All Treated Attacks (Analysis Population)

A



B



Analysis population is defined as all randomized patients who received at least 1 dose of ubrogepant and had at least 1 posttreatment efficacy assessment in this trial.
Pain Freedom is a reduction in headache severity from mild/moderate/severe at baseline to no headache pain.
N1 is the total number of participants and N2 is the total number of treated attacks.
Responder rates, odds ratios, 95% confidence intervals, and p-values are based on a generalized linear mixed model that addresses within participant correlation.
All available data are used in the analysis.

eFigure 3. Pain Freedom at A) 24 Hours and B) 48 Hours Post Dose by Headache Severity Across All Treated Attacks in the Subgroup who Treated Both Mild and Moderate or Severe Attacks

A



B



Pain Freedom is a reduction in headache severity from mild/moderate/severe at baseline to no headache pain.
N1 is the total number of participants and N2 is the total number of treated attacks.
Responder rates, odds ratios, 95% confidence intervals, and p-values are based on a generalized linear mixed model that addresses within participant correlation.
All available data are used in the analysis.

eFigure 4. Absence of Migraine-associated Symptoms at A) 24 Hours and B) 48 Hours Post Dose by Headache Severity Across All Treated Attacks (Analysis Population)

A



B



Analysis population is defined as all randomized patients who received at least 1 dose of ubrogepant and had at least 1 posttreatment efficacy assessment in this trial.
Absence of symptom includes data for all treated attacks regardless of presence/absence of the symptom for the treated attack.
N1 is the total number of participants and N2 is the total number of treated attacks.
Responder rates, odds ratios, 95% confidence intervals, and p-values are based on a generalized linear mixed model that addresses within participant correlation.
All available data are used in the analysis.

eFigure 5. Absence of Migraine-associated Symptoms at A) 2 Hours, B) 24 Hours, and C) 48 Hours Post Dose by Headache Severity Across All Treated Attacks in the Subgroup who Treated Both Mild and Moderate or Severe Attacks

A



B



C



Absence of symptom includes data for all treated attacks regardless of presence/absence of the symptom for the treated attack.
N1 is the total number of participants and N2 is the total number of treated attacks.
Responder rates, odds ratios, 95% confidence intervals, and p-values are based on a generalized linear mixed model that addresses within participant correlation.
All available data are used in the analysis.

eFigure 6. Use of an Optional Second Dose of Trial Treatment within A) 24 Hours and B) 48 Hours Post Dose by Headache Severity Across All Treated Attacks (Analysis Population)

A



B



Analysis population is defined as all randomized patients who received at least 1 dose of ubrogepant and had at least 1 posttreatment efficacy assessment in this trial.
An optional second dose of trial treatment was allowed 2 hours after the initial dose for mild, moderate, or severe headache.
N1 is the total number of participants and N2 is the total number of treated attacks.
Responder rates, odds ratios, 95% confidence intervals, and p-values are based on a generalized linear mixed model that addresses within participant correlation.
All available data are used in the analysis.

eFigure 7. Use of Rescue Medication within A) 24 Hours and B) 48 Hours Post Dose by Headache Severity Across All Treated Attacks (Analysis Population)

A



B



Analysis population is defined as all randomized patients who received at least 1 dose of ubrogepant and had at least 1 posttreatment efficacy assessment in this trial.
Rescue medication was allowed 2 hours after the initial dose for mild, moderate, or severe headache.
N1 is the total number of participants and N2 is the total number of treated attacks.
Responder rates, odds ratios, 95% confidence intervals, and p-values are based on a generalized linear mixed model that addresses within participant correlation.
All available data are used in the analysis.